BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In the late 1990s, recognizing CML's dependency on BCR::ABL expression, several ABL tyrosine kinase inhibitors (TKIs) were developed and currently represent the first line of treatment for CML.